Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
04 04 2022
Historique:
received: 03 02 2022
revised: 31 03 2022
accepted: 02 04 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.

Identifiants

pubmed: 35409996
pii: ijerph19074314
doi: 10.3390/ijerph19074314
pmc: PMC8998351
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Discov Med. 2011 Nov;12(66):445-53
pubmed: 22127115
Breast Cancer Res Treat. 2012 Jul;134(2):889-94
pubmed: 22739995
BMC Cancer. 2015 Jul 17;15:523
pubmed: 26183948
Ugeskr Laeger. 2006 Jun 12;168(24):2367-9
pubmed: 16822422
Cancer. 2015 Feb 1;121(3):372-8
pubmed: 25236687
Mol Biol Rep. 2012 Mar;39(3):2109-18
pubmed: 21643751
N Engl J Med. 1997 May 15;336(20):1401-8
pubmed: 9145676
Int J Cancer. 2004 Jul 10;110(5):683-6
pubmed: 15146557
Breast Cancer Res Treat. 2015 May;151(1):157-68
pubmed: 25863477
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
JAMA. 2006 Mar 22;295(12):1379-88
pubmed: 16551709
Oncol Rep. 2013 Sep;30(3):1019-29
pubmed: 23779253
J BUON. 2020 May-Jun;25(3):1337-1347
pubmed: 32862574
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biomed Res Int. 2013;2013:928562
pubmed: 24312913
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
pubmed: 23628597
Am J Hum Genet. 1997 May;60(5):1013-20
pubmed: 9150148
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Cancer Res. 1999 Apr 15;59(8):2011-7
pubmed: 10213514
EPMA J. 2010 Sep;1(3):397-412
pubmed: 23199084

Auteurs

Radu Vidra (R)

Oncology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.
Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", 400000 Cluj-Napoca, Romania.

Tudor Eliade Ciuleanu (TE)

Oncology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

Adina Nemeș (A)

Oncology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

Oana Pascu (O)

The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

Ana Maria Heroiu (AM)

The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

Nicoleta Antone (N)

The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

Andreea Iulia Vidrean (AI)

Medisprof Cancer Center, 400641 Cluj-Napoca, Romania.

Cristina Marinela Oprean (CM)

Department of Oncology, ONCOHELP Hospital, 200239 Timisoara, Romania.
ANAPATMOL Research Center, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Department of Oncology, ONCOMED Outpatient Unit Timisoara, 300239 Timisoara, Romania.

Laura Ancuta Pop (LA)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Ioana Berindan-Neagoe (I)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Rares Eniu (R)

Faculte de Medecine, Universite de Geneve, 1206 Geneva, Switzerland.

Alexandru Eniu (A)

Hopital Riviera-Chablais, 1847 Rennaz, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH